Business Context and Reporting Period
Perspective Therapeutics, Inc. (NYSE American: CATX) filed a Form 8-K on February 2, 2026. The filing reports the update and public release of the Company's corporate presentation, which includes preliminary estimated financial data as of December 31, 2025.
Key Financial Metrics
The filing references estimated cash, cash equivalents, and short-term investments as of December 31, 2025, contained within the attached corporate presentation. However, the filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The data is described as preliminary, unaudited, and subject to final adjustments upon the completion of year-end closing procedures.
Material Changes
No material changes to financial results or operations are detailed in the text of this filing. The document serves solely to disclose the availability of updated projected financial information in a separate presentation.
Guidance, Outlook, and Risks
- Management Commentary: The Company notes that the financial information in the presentation is estimated and projected.
- Contingencies and Risks: The filing explicitly states that the independent registered public accounting firm, WithumSmith+Brown, PC, has not performed any procedures on the preliminary data and expresses no opinion or assurance regarding it. Actual results as of December 31, 2025, may differ from the preliminary data due to final closing procedures and other developments.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) for specific numerical values regarding cash, cash equivalents, and short-term investments.
- Verify the final audited financial statements for the fiscal year ended December 31, 2025, once released, to confirm if actual results align with the preliminary estimates.
- Monitor future filings for any material adjustments to the preliminary data disclosed in the presentation.